Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ: ARVN )

8.550 -0.480 (-5.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,416,021
Open 8.900
Bid (Size) 8.450 (1)
Ask (Size) 8.840 (1)
Prev. Close 9.030
Today's Range 8.430 - 9.545
52wk Range 7.914 - 46.62
Shares Outstanding 68,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga

Performance

YTD
-54.74%
-54.74%
1 Month
-54.93%
-54.93%
3 Month
-62.07%
-62.07%
6 Month
-65.65%
-65.65%
1 Year
-81.20%
-81.20%

More News

Read More
Tuesday's session: top gainers and losers
Via Chartmill
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Via Benzinga
These Analysts Revise Their Forecasts On Arvinas After Q4 Results
Via Benzinga
What 4 Analyst Ratings Have To Say About Arvinas
Via Benzinga
Demystifying Arvinas: Insights From 5 Analyst Reviews
Via Benzinga
Gapping stocks in Tuesday's session
Via Chartmill
Crude Oil Gains 1%; Ciena Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Via Investor's Business Daily
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
US Stocks Mixed; Kohl's Shares Plunge After Q4 Results
Via Benzinga
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Snowflake To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?
Via Benzinga
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Earnings Scheduled For February 11, 2025
Via Benzinga
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Arvinas Inc.
Via GlobeNewswire
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
Via The Motley Fool
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients
Via Benzinga
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.